Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV6GX7)

Drug Name

ONO-7475 Drug Info

Synonyms

1646839-59-9; UNII-0VCB95RHRV; N-(5-((6,7-Dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[5-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-3-quinolinecarboxamide; SCHEMBL16426362; ONO7475; BCP33232; MFCD32689448; s8933; ONO-7475; ONO 7475; HY-114358; CS-0083699; 3-Quinolinecarboxamide, N-(5-((6,7-dimethoxy-4-quinolinyl)oxy)-2-pyridinyl)-1,2,5,6,7,8-hexahydro-2,5-dioxo-1-phenyl-; N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-2,5-dioxo-1-phenyl-7,8-dihydro-6H-quinoline-3-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Acute leukaemia	2A60	Phase 1/2	[1]
Myelodysplastic syndrome	2A37	Phase 1/2	[1]
Acute myeloid leukaemia	2A60	Phase 1	[2]

Cross-matching ID

PubChem CID: 90645873
CAS Number: CAS 1646839-59-9
TTD Drug ID: DMV6GX7

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tyrosine-protein kinase Mer (MERTK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[3]
RXDX-106	DM6NVTR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
MRX-2843	DMM5N8P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
PF-07265807	DMSMNRQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
INCB81776	DMFOXGB	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
LDC1267	DMH7R6L	Discovery agent	N.A.	Investigative	[8]
G749	DMC7HIS	Discovery agent	N.A.	Investigative	[9]
UNC2025	DMCU59W	Glioblastoma of brain	2A00.00	Investigative	[10]
UNC569	DMJL6ZM	Acute lymphoblastic leukaemia	2A85	Investigative	[11]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[3]
RXDX-106	DM6NVTR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
MRX-2843	DMM5N8P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
PF-07265807	DMSMNRQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
INCB81776	DMFOXGB	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
LDC1267	DMH7R6L	Discovery agent	N.A.	Investigative	[8]
G749	DMC7HIS	Discovery agent	N.A.	Investigative	[9]
UNC2025	DMCU59W	Glioblastoma of brain	2A00.00	Investigative	[10]
UNC569	DMJL6ZM	Acute lymphoblastic leukaemia	2A85	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 18 Drug(s)

Drug(s) Targeting Tyrosine-protein kinase UFO (AXL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[2]
MGCD265	DMRPCF2	Non-small-cell lung cancer	2C25.Y	Phase 2	[12]
BI-505	DMSZQHX	Multiple myeloma	2A83	Phase 2	[13]
Bemcentinib	DM0YCPL	Myelodysplastic syndrome	2A37	Phase 2	[14]
BGB-324	DMDI43Y	Breast cancer	2C60-2C65	Phase 2	[15]
Mecbotamab vedotin	DMU5KH4	Ovarian cancer	2C73	Phase 2	[16]
TP-0903	DMHTG8P	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[2]
Enapotamab vedotin	DM1PQJO	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[17]
RXDX-106	DM6NVTR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
BPI-9016 M	DMNY0U5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
Gilteritinib	DMTI0ZO	Acute myeloid leukaemia	2A60	Approved	[2]
MGCD265	DMRPCF2	Non-small-cell lung cancer	2C25.Y	Phase 2	[12]
BI-505	DMSZQHX	Multiple myeloma	2A83	Phase 2	[13]
Bemcentinib	DM0YCPL	Myelodysplastic syndrome	2A37	Phase 2	[14]
BGB-324	DMDI43Y	Breast cancer	2C60-2C65	Phase 2	[15]
Mecbotamab vedotin	DMU5KH4	Ovarian cancer	2C73	Phase 2	[16]
TP-0903	DMHTG8P	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[2]
Enapotamab vedotin	DM1PQJO	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[17]
RXDX-106	DM6NVTR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
BPI-9016 M	DMNY0U5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine-protein kinase Mer (MERTK)	TTO7LKR	MERTK_HUMAN	Inhibitor	[2]
Tyrosine-protein kinase UFO (AXL)	TTZPY6J	UFO_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03176277) A Study of ONO-7475 in Patients With Acute Leukemias. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
4	National Cancer Institute Drug Dictionary (drug name RXDX106).
5	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630.
6	National Cancer Institute Drug Dictionary (drug name PF-07265807).
7	A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477.
8	The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12.
9	G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19.
10	MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018 Jan 10;20(1):92-102.
11	UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77.
12	Company report (Mirati Therapeutics: formerly MethylGene)
13	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
14	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999.
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835).
16	Clinical pipeline report, company report or official report of BioAtla
17	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199.
18	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.